Causes of Positive Pretransplant Crossmatches in the Absence of Donor-Specific Anti-Human Leukocyte Antigen Antibodies: A Single-Center Experience
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Pretransplant crossmatch (XM) testing is widely used for detecting preformed donor-specific antibodies (DSAs) against human leukocyte antigen (HLA). However, in some cases, there is a positive XM result in the absence of HLA-DSAs, the cause of which was rarely identified. We reviewed the causes of sequential positive XM results at a single center and analyzed the presence of non-HLA antibodies in patients with an unexplained positive pretransplant XM result. Among 251 patients with T-cell/B-cell complement-dependent cytotoxicity (CDC) or flow cytometric crossmatch (FCXM) positivity, HLA-DSAs were confirmed in 88 (35.1%) by a single antigen bead (SAB) assay, 150 (59.8%) used rituximab (anti-CD20), and 13 (5.2%) had neither HLA-DSAs nor a desensitization history. Anti-angiotensin II type 1 receptor IgG and 33 non-HLA antibodies were tested in the 13 patients with an unexplained positive pretransplant XM result, and more than one non-HLA antibody were revealed in all these patients; 11 patients had non-HLA antibodies reported to be associated with graft rejection, and two patients experienced rejection episode after kidney transplantation. Our study suggests considering non-HLA antibodies testing when a CDC or FCXM test is positive without a definite cause. Assessing non-HLA antibodies might be useful for interpreting XM results and evaluating immunologic risk in transplant recipients.
Abstract
Pretransplant crossmatch (XM) testing is widely used for detecting preformed donor-specific antibodies (DSAs) against human leukocyte antigen (HLA). However, in some cases, there is a positive XM result in the absence of HLA-DSAs, the cause of which was rarely identified. We reviewed the causes of sequential positive XM results at a single center and analyzed the presence of non-HLA antibodies in patients with an unexplained positive pretransplant XM result. Among 251 patients with T-cell/B-cell complement-dependent cytotoxicity (CDC) or flow cytometric crossmatch (FCXM) positivity, HLA-DSAs were confirmed in 88 (35.1%) by a single antigen bead (SAB) assay, 150 (59.8%) used rituximab (anti-CD20), and 13 (5.2%) had neither HLA-DSAs nor a desensitization history. Anti-angiotensin II type 1 receptor IgG and 33 non-HLA antibodies were tested in the 13 patients with an unexplained positive pretransplant XM result, and more than one non-HLA antibody were revealed in all these patients; 11 patients had non-HLA antibodies reported to be associated with graft rejection, and two patients experienced rejection episode after kidney transplantation. Our study suggests considering non-HLA antibodies testing when a CDC or FCXM test is positive without a definite cause. Assessing non-HLA antibodies might be useful for interpreting XM results and evaluating immunologic risk in transplant recipients.
참고문헌 (19)
- Mulley WR, "Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist", Nephrol (Carlton), 16, pp.125~133 (2011)
- Kumar A, "An update on crossmatch techniques in transplantation", J Kidney, 3, pp.4~ (2017)
- Milongo D, "Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results", Transpl Immunol, 32, pp.151~155 (2015)
- Park H, "Frequent false-positive reactions in pronase-treated T-cell flow cytometric cross-match tests", Transplant Proc, 44, pp.87~90 (2012)
- Zhang Q, "The importance of non-HLA antibodies in transplantation", Nat Rev Nephrol, 12, pp.484~495 (2016)
- Cardinal H, "The emerging importance of non-HLA autoantibodies in kidney transplant complications", J Am Soc Nephrol, 28, pp.400~406 (2017)
- 민지원, "Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients", Annals of Laboratory Medicine, 38(5), pp.450~457 (2018), 대한진단검사의학회[DOI]
- Shinae Yu, "Pre-Transplant Angiotensin II Type 1 Receptor Antibodies and Anti-Endothelial Cell Antibodies Predict Graft Function and Allograft Rejection in a Low-Risk Kidney Transplantation Setting", Annals of Laboratory Medicine, 40(5), pp.398~408 (2020), 대한진단검사의학회[DOI]
- Aguilera I, "Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients", Nephrol Dial Transplant, 23, pp.2393~2398 (2008)
- Dinavahi R, "Antibodies reactive to non-HLA antigens in transplant glomerulopathy", J Am Soc Nephrol, 22, pp.1168~1178 (2011)
- Li L, "Differential immunogenicity and clinical relevance of kidney compartment specific antigens after renal transplantation", J Proteome Res, 9, pp.6715~6721 (2010)
- Sigdel TK, "Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury", J Am Soc Nephrol, 23, pp.750~763 (2012)
- Sigdel TK, "Moving beyond HLA: a review of nHLA antibodies in organ transplantation", Hum Immunol, 74, pp.1486~1490 (2013)
- 이혜영, "Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection", Annals of Laboratory Medicine, 35(3), pp.314~320 (2015), 대한진단검사의학회
- Hamrick C, "Flow cytometric T and B cell crossmatching. ASHI laboratory manual", pp.41~45 (2000), American Society for Histocompatibility and Immunogenetics
- 김훈석, "EDTA Treatment for Overcoming the Prozone Effect and for Predicting C1q Binding in HLA Antibody Testing", Annals of Laboratory Medicine, 39(6), pp.572~576 (2019), 대한진단검사의학회[DOI]
- Chung BH, "Clinical impact of the baseline donor‐specific anti‐human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy", Transpl Int, 27, pp.49~59 (2014)
- Angaswamy N, "Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy", Am J Transplant, 14, pp.685~693 (2014)
- Zhang X, "Impact of non-human leukocyte antigen-specific antibodies in kidney and heart transplantation", Front Immunol, 8, pp.434~ (2017)